公开(公告)号：US20250092139A1

公开(公告)日：2025-03-20

申请号：US18442255

申请日：2024-02-15

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Nicholas J. Papadopoulos ,  Andrew J. Murphy ,  Gavin Thurston ,  Ella Ioffe ,  Elena Burova

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/22 ,  C07K16/30

Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand 1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.

公开(公告)号：US12239111B2

公开(公告)日：2025-03-04

申请号：US17385039

申请日：2021-07-26

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Li-Hsien Wang ,  Anthony T. Dore, Jr. ,  Sean Stevens ,  Andrew J. Murphy

IPC: A01K67/0278 ,  C07K14/54 ,  C07K14/715 ,  C12N5/0735 ,  C12N5/10 ,  C12N5/16 ,  C12N15/90

Abstract: Mice that comprise a replacement of endogenous mouse IL-6 and/or IL-6 receptor genes are described, and methods for making and using the mice. Mice comprising a replacement at an endogenous IL-6Rα locus of mouse ectodomain-encoding sequence with human ectodomain-encoding sequence is provided. Mice comprising a human IL-6 gene under control of mouse IL-6 regulatory elements is also provided, including mice that have a replacement of mouse IL-6-encoding sequence with human IL-6-encoding sequence at an endogenous mouse IL-6 locus.

公开(公告)号：US12127537B2

公开(公告)日：2024-10-29

申请号：US17316266

申请日：2021-05-10

Applicant: Regeneron Pharmaceuticals, Inc. ,  Yale University ,  Institute for Research in Biomedicine (IRB)

Inventor： Richard Flavell ,  Markus Manz ,  Anthony Rongvaux ,  Till Strowig ,  Tim Willinger ,  Andrew J. Murphy ,  Sean Stevens ,  George Yancopoulos

IPC: A01K67/0278 ,  A01K67/0271 ,  C12N15/87

CPC classification number: A01K67/0278 ,  A01K67/0271 ,  C12N15/87 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0381 ,  A01K2267/0387

Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.

公开(公告)号：US20240306616A1

公开(公告)日：2024-09-19

申请号：US18442444

申请日：2024-02-15

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Kara L. Olson ,  Eric Smith ,  Ka-Man Venus Lai ,  Andrew J. Murphy ,  Gavin Thurston ,  Dayong Guo

IPC: A01K67/0278 ,  A01K67/0276 ,  C07K14/725 ,  C12N5/071 ,  C12N15/85 ,  G01N33/50

CPC classification number: A01K67/0278 ,  A01K67/0276 ,  C07K14/7051 ,  C12N5/0602 ,  C12N15/8509 ,  G01N33/5088 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  A01K2267/0337 ,  Y02A50/30

Abstract: Non-human animals, expressing humanized CD3 proteins are provided. Non-human animals, e.g., rodents, genetically modified to comprise in their genome humanized CD3 proteins are also provided. Additionally, provided are methods and compositions of making such non-human animals, as well as methods of using said non-human animals.

公开(公告)号：US20240298619A1

公开(公告)日：2024-09-12

申请号：US18316461

申请日：2023-05-12

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Elena Burova ,  Alexander O. Mujica ,  Ka-Man Venus Lai ,  Andrew J. Murphy

IPC: A01K67/0278 ,  A61K49/00 ,  C07K14/435 ,  C07K14/47 ,  C07K16/28 ,  C12Q1/6886 ,  G01N33/50

CPC classification number: A01K67/0278 ,  A61K49/0008 ,  C07K14/4747 ,  C07K16/2803 ,  C12Q1/6886 ,  G01N33/5038 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/0331 ,  C07K14/435 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/57 ,  G01N2333/70503 ,  G01N2500/10

Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. The non-human animals, in some embodiments, comprise a genetic modification to an endogenous Pdcd1 gene so that the non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).

公开(公告)号：US12037388B2

公开(公告)日：2024-07-16

申请号：US17388322

申请日：2021-07-29

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Andrew J. Murphy ,  Nicholas J. Papadopoulos ,  Jamie M. Orengo

IPC: C07K16/24 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K39/395 ,  A61K2300/00

Abstract: The present invention provides antibodies that bind to interleukin-33 (IL-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate IL-33-mediated signaling. The antibodies of the invention may function to block the interaction between IL-33 and ST2. Alternatively, certain antibodies of the invention inhibit or attenuate IL-33-mediated signaling without blocking the IL-33/ST2 interaction. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human IL-33 with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as inflammatory diseases, or allergic diseases.

公开(公告)号：US12010979B2

公开(公告)日：2024-06-18

申请号：US18057960

申请日：2022-11-22

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Meghan Drummond Samuelson ,  Jeffery Haines ,  Suzanne Hartford ,  David Frendewey ,  Brian Zambrowicz ,  Andrew J. Murphy

IPC: A01K67/0278 ,  A01K67/0275 ,  A61K48/00 ,  C07K14/47 ,  C12N15/113 ,  C12N15/86

CPC classification number: A01K67/0275 ,  A01K67/0278 ,  A61K48/0041 ,  C07K14/47 ,  C12N15/113 ,  C12N15/86 ,  A01K2207/15 ,  A01K2217/058 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/0306 ,  C07K2319/02 ,  C12N2310/20 ,  C12N2710/10041

Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus and methods of using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR. Methods are also provided for making such non-human animals comprising a humanized TTR locus.

公开(公告)号：US20240065238A1

公开(公告)日：2024-02-29

申请号：US18137110

申请日：2023-04-20

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn Macdonald ,  Sean Stevens ,  Andrew J. Murphy ,  Margaret Karow ,  John McWhirter

IPC: A01K67/027 ,  C07K16/46 ,  C12P21/02

CPC classification number: A01K67/0278 ,  A01K67/0276 ,  C07K16/461 ,  C12P21/02 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105

Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.

公开(公告)号：US20230337646A1

公开(公告)日：2023-10-26

申请号：US18110276

申请日：2023-02-15

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn Macdonald ,  Cagan Gurer ,  Karolina A. Hosiawa ,  Sean Stevens ,  Andrew J. Murphy

IPC: A01K67/027 ,  C07K16/46 ,  C12N9/64 ,  C07K16/28

CPC classification number: A01K67/0278 ,  C07K16/462 ,  C12N9/6489 ,  C07K16/2866 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  C12N2800/204 ,  C12N2800/30

Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.

公开(公告)号：US11778995B2

公开(公告)日：2023-10-10

申请号：US17000140

申请日：2020-08-21

Applicant: Regeneron Pharmaceuticals, Inc. ,  Yale University ,  Institute for Research In Biomedicine (IRB)

Inventor： Richard Flavell ,  Till Strowig ,  Markus G. Manz ,  Chiara Borsotti ,  Madhav Dhodapkar ,  Andrew J. Murphy ,  Sean Stevens ,  George D. Yancopoulos

IPC: A01K67/027 ,  C07K14/535 ,  C07K14/54 ,  C07K14/52 ,  A61K49/00

CPC classification number: A01K67/0278 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A61K49/0008 ,  C07K14/524 ,  C07K14/535 ,  C07K14/5403 ,  C07K14/5412

Abstract: Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.